TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04301336

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxy Urea
Description: 50 patients from each participating hospital that will receive the ordinary treatment of Hydroxyurea (20 mg/kg/day) with monitoring blood count every 2 weeks maximum daily dose: (40 mg/kg/day) for 8 consecutive months up to 10 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxy Urea
Description: 50 patients from each participating hospital that will receive the ordinary treatment of Hydroxyurea (20 mg/kg/day) with monitoring blood count every 2 weeks maximum daily dose: (40 mg/kg/day) for 8 consecutive months up to 10 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxy Urea
Description: 50 patients from each participating hospital that will receive the ordinary treatment of Hydroxyurea (20 mg/kg/day) with monitoring blood count every 2 weeks maximum daily dose: (40 mg/kg/day) for 8 consecutive months up to 10 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxy Urea
Description: 50 patients from each participating hospital that will receive the ordinary treatment of Hydroxyurea (20 mg/kg/day) with monitoring blood count every 2 weeks maximum daily dose: (40 mg/kg/day) for 8 consecutive months up to 10 months.
Study: NCT01021683

Intervention type: DRUG
Intervention: Itraconazole
Description: Itraconazole will be administered as an infusion (a fluid or a medicine delivered into a vein by way of a needle) over one hour at the dose of 200 milligram (mg) per dose twice daily for 2 days, followed by 200 mg once daily for 12 days, followed by itraconazole oral solution at the dose of 200 mg per dose twice daily for 14 days until clinically significant neutropenia is recovered.
Study: NCT01817868

Intervention type: OTHER
Intervention: Recombinant Factor VIII (Kogenate, BAY14-2222)
Description: All dosage, frequency and duration for drugs will be under the decision of the treating physician.
Study: NCT00606372

Intervention type: PROCEDURE
Intervention: OPCAB - the off-pump coronary artery bypass
Description: surgical myocardial revascularisation without use of cardio-pulmonary bypass, using stabilising devices on beating heart
Study: NCT01440153

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Participants from group A receive an active program aiming at improving their cardiovascular endurance, muscular strength and motor control. The level for cardiovascular training is based on the results of the maximal exercise test performed during baseline assessment. The level of training is determined at a level of 70% of the predicted maximal heart rate and was increased every 6 weeks with 5%, ending at 85%. Heart rate will be monitored during the training.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Passive Intervention
Description: Participants from group B will receive an alternative program, in which all active parts are replaced by passive interventions. Several education sessions will be given regarding different topics, such as stress management, nutrition, injuries, etc. In addition, also practical sessions well be held to practice massage, passive stretching, taping.
Study: NCT04745182

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MASTERY
Description: A 12-week, phone-delivered intervention utilizing positive psychology (PP), motivational interviewing (MI), and specific midlife modules (e.g., on time management, financial stress, caregiving stress, or occupational stress) to promote physical activity and well-being in mid-life adults.
Study: NCT03588208

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Progressive resistance training program
Description: Progressive resistance training program were performed twice a week for 12 weeks. The charge intensity was progressively increased from 40% to 80% of 1 repetition maximum. The following muscle groups were worked: trunk flexors and extensors, elbow flexors and extensors, knee flexors and extensors, hip abductors and adductors and shoulder abductors. In addition to strength training.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Educational Program
Description: Structured education program were performed during one hour class once a week for five weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Program
Description: Structured education program were performed during one hour class once a week for five weeks
Study: NCT00315250

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [123I]β-CIT
Description: Single Photon Emission Computed Tomography~SPECT imaging uses the single photon emissions from radioactive compounds that are (most commonly) injected into a patient and are metabolized by specific organs or body systems. SPECT imaging is performed by using a gamma camera to acquire multiple 2-D images (also called projections), from multiple angles. A computer is then used to apply a tomographic reconstruction algorithm to the multiple projections, yielding a 3-D dataset. This dataset may then be manipulated to show thin slices along any chosen axis of the body, similar to those obtained from other tomographic techniques, such as MRI, CT, and PET. The resulting SPECT images reflect body/organ function as opposed to specific anatomy of other imaging modalities such as CT or MRI.
Study: NCT01763931

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Description: Digoxin once daily for 2 weeks prior to definitive breast surgery.
Study: NCT02081846

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nurse Home Visit
Description: We will complete a single center, parallel, randomized, standard-of-care-controlled prospective study to determine the efficacy of a nurse home visit program, an intervention adapted from those studied in other populations (i.e., adults, high-risk infants) and re-engineered through Aim 2, in improving pediatric patient transitions from hospital to home

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Control patients will be randomized to receive standard-of-care at discharge. This care at our institution includes pediatric hospitalist to PCP (primary care physician) verbal and written communication prior to discharge, written documentation for the family regarding prescribed medication regimen, recommended follow-up with outpatient PCP and relevant consultant(s), and delivery of prescribed medications from the hospital pharmacy to the patient's bedside.
Study: NCT02804854

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neutrophil Activation Probe (NAP)
Description: Delivery of NAP by direct pulmonary administration followed by fibreoptic confocal microendoscopy. A total of 240 mcg (±25%) in three divided doses of 80 mcg (±25%).
Study: NCT06119633

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Immediate tissue expander and lipofilling after mastectomy
Description: Implant-based breast reconstruction and fat grafting after salvage or prophylactic mastectomy in patients previously exposed to radiation therapy on the breast as adjuvant treatment after breast conserving surgery (BCS) or on thoracic wall for Hodgkin Lymphoma (HL).
Study: NCT04019938

Intervention type: RADIATION
Intervention: Dual-energy X-ray absorptiometry
Description: Cystatin C is measured as a part of routine investigation at the time of admission.
Study: NCT02955511

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Blade MAC size 3
Description: Patient will be intubated using the DL- Blade MAC size 3

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Blade MAC size 3.5
Description: Patient will be intubated using the DL- Blade MAC size 3.5

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Inscope Blade size 3.5
Description: Patient will be intubated using the Inscope Blade size 3.5
Study: NCT03913741

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tisotumab vedotin
Description: Tisotumab vedotin will be administered intravenously once every 21 days. The dose levels will be determined by the starting dose and the escalation steps taken in the trial
Study: NCT01158131

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Balance after Baby Lifestyle Intervention Program
Description: Participants in this intervention will receive support from a lifestyle coach and gain access to a website with online presentations that contain healthy eating and physical activity educational tips. Weekly phone conversations with the lifestyle coach, as well as logging diet and physical activity will also be required of intervention participants.
Study: NCT02715921

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tele-exercise
Study: NCT04721054

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thoracic epidural effect on heart rate in Laparoscopic Cholecystectomy (bupivacaine and lignocaine)
Description: patients in epidural anesthesia were given epidural anesthesia and assessed for heart rate and mean arterial pressure

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: general anesthesia effect on heart rate in Laparoscopic Cholecystectomy
Description: patients in general anesthesia were given epidural anesthesia and assessed for heart rate and mean arterial pressure
Study: NCT02698072

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic exercise
Description: 20-25 minutes aerobic exercise, 20-25 minutes strength exercise and 10-15 minutes stretch exercise.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic exercise
Description: 20-25 minutes aerobic exercise, 20-25 minutes strength exercise and 10-15 minutes stretch exercise.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dry needling
Description: Dry needling needle AGUPUNT®

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sham dry needling
Description: Sham dry needling DONGBANG-ACUPRIME®
Study: NCT01566045

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Core Needle TRUS Needle biopsy (Transrectal ultrasound)
Description: Standard of care 12-core TRUS sextant needle biopsy of the medial and lateral margins of the right and left apex, mid-gland and base of the prostate

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Core Needle MRI/US image fusion guided needle biopsy
Description: Directed prostate needle biopsies at MR-image identified targets in addition to the standard ultrasound 12-14 core biopsies
Study: NCT01953081

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-8954

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoclopramide
Study: NCT03819660

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amifampridine Phosphate 10 MG Oral Tablet
Description: Oral tablets
Study: NCT03835533

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NKTR-214 (Cohort A)
Description: NKTR-214 will be administered intravenously every 3 weeks for up to 2 years

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab (Cohort A, B and C)
Description: Nivolumab will be administered intravenously every 3 weeks for up to 2 years to cohort A, every 4 weeks for up to 2 years for cohort B and C.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab (Cohort A, B and C)
Description: Nivolumab will be administered intravenously every 3 weeks for up to 2 years to cohort A, every 4 weeks for up to 2 years for cohort B and C.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab (Cohort A, B and C)
Description: Nivolumab will be administered intravenously every 3 weeks for up to 2 years to cohort A, every 4 weeks for up to 2 years for cohort B and C.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiation therapy (SBRT) (Cohort B)
Description: Radiation therapy will be administered at 30 - 50 Gy in 1 - 5 doses, starting on Day 1 or 2 of Cycle 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDX-301 (Cohort B and C)
Description: CDX-301 will be subcutaneously once a day for 5 days for cohort B. CDX-301 will be subcutaneously once a day for 10 days of immune-priming lead-in for cohort C.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDX-301 (Cohort B and C)
Description: CDX-301 will be subcutaneously once a day for 5 days for cohort B. CDX-301 will be subcutaneously once a day for 10 days of immune-priming lead-in for cohort C.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Poly-ICLC (Cohort B)
Description: Poly-ICLC will be administered intramuscularly twice weekly for 3 weeks starting on Day 1 of Cycle 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INO-5151 (Cohort C)
Description: INO-5151 will be administered intramuscularly on Day 8 of the Immune-priming Lead-in, and on day 1 of Cycle 1, 2 and 3, then every 12 weeks thereafter

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cellectra 2000
Description: Electroporation device
Study: NCT00735046

Intervention type: BEHAVIORAL
Intervention: Cognitive behavioral therapy for early Alzheimer's disease
Description: 12 weekly individual sessions, total duration 3 months, regular involvement of patient's proxy ever second session. Intervention is manualized but is flexible with regard to individual resources and needs.

Intervention type: OTHER
Intervention: Control
Description: Patients and proxies who are assigned to treatment as usual
Study: NCT00507455

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: solifenacin succinate
Description: Solifenacin succinate tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: solifenacin succinate
Description: Solifenacin succinate tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tamsulosin hydrochloride
Description: Tamsulosin hydrochloride Oral Control Absorption System (TOCAS) tablets
Study: NCT02936739

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anterior cervical discectomy with prosthetic disc replacement / ESP.
Description: Anterior cervical discectomy, with the use of the ESP prosthesis (Manufacturer: FH orthopedics, Mulhouse, France) for the disc replacement.
Study: NCT00507455

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tamsulosin hydrochloride
Description: Tamsulosin hydrochloride Oral Control Absorption System (TOCAS) tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to solifenacin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to tamsulosin
Study: NCT02182115

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: antiseptic bundle
Description: 1. Chlorhexidine gluconate liquid soap for bathing daily.~2. Chlorhexidine gluconate mouthrinse to use twice daily.~3. Nasal mupirocin to apply twice daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard of care
Description: Surgeon's instructions may include advising patients to use an antiseptic soap prior to surgery.
Study: NCT03710967

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation
Description: Transcranial magnetic stimulation of the primary motor cortex

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial magnetic stimulation
Description: Transcranial magnetic stimulation of the primary motor cortex
Study: NCT03123393

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-659
Description: TAK-659 Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-659
Description: TAK-659 Tablets
Study: NCT02435537

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine (Precedex)
Description: intrathecal administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: intrathecal 10 mg bupivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: intrathecal 10 mg bupivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: intrathecal 10 mg bupivacaine
Study: NCT02936739

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Anterior cervical discectomy with prosthetic disc replacement / Rotaio.
Description: Anterior cervical discectomy, with the use of the Rotaio prosthesis (Manufacturer: Signus Med, Alzenau, Germany) for the disc replacement.
Study: NCT04652050

Intervention type: DRUG
Intervention: Tolsura
Description: Patients fulfilling the inclusion criteria (see above) and placed on Tolsura for prophylaxis, and signed informed consent to participate in this study will be part of the study.
Study: NCT02946788

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline
Description: BPX-01 1 or 2% topical gel will be applied to face once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline
Description: BPX-01 1 or 2% topical gel will be applied to face once daily
Study: NCT00586430

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lorazepam
Description: single 2 mg dose of lorazepam

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: single dose of placebo
Study: NCT02089984

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet Based CBT Training
Study: NCT02832453

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle
Description: The counselling program consists of 6 group meetings of 1 hour and 3 individual consultations of at least 15 minutes each. Sessions will be set up with the aim to enhance knowledge and empowerment related to physical activity, sedentary conducts, dietary habits, as well as strategies for behaviour change will be given. Individual consultations will focus on establishing realistic objectives and to involve the participants in taking decisions.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Lifestyle
Description: The counselling program consists of 6 group meetings of 1 hour and 3 individual consultations of at least 15 minutes each. Sessions will be set up with the aim to enhance knowledge and empowerment related to physical activity, sedentary conducts, dietary habits, as well as strategies for behaviour change will be given. Individual consultations will focus on establishing realistic objectives and to involve the participants in taking decisions.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle
Description: The counselling program consists of 6 group meetings of 1 hour and 3 individual consultations of at least 15 minutes each. Sessions will be set up with the aim to enhance knowledge and empowerment related to physical activity, sedentary conducts, dietary habits, as well as strategies for behaviour change will be given. Individual consultations will focus on establishing realistic objectives and to involve the participants in taking decisions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic interval training
Description: The supervised aerobic interval training will consist of 16 supervised group training lessons lasting 60 minutes and 32 individual nonsupervised training lessons that would be self-administered by each participant. The main part of the training lessons will consist of 4 series of 4 minutes of cycling at a heart rate of 80% of the VO2peak interspersed with active pauses of 2 minutes at 60% of the VO2peak .

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional continous training
Description: The supervised traditional continous training will consist of 16 supervised group training lessons lasting 60 minutes and 32 individual nonsupervised training lessons that would be self-administered by each participant. The main part of the training lessons will consist of activities such as walking, cycling, or tonification exercises always at an intensity of 60% of the VO2peak.
Study: NCT02965599

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3117391
Description: GSK3117391 (Dose A) is a white, opaque, gelatin capsule.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is a white, opaque, gelatin capsule.
Study: NCT01550783

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cervical Papanicolaou Test
Description: Undergo standard of care Pap test screening

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cytology Specimen Collection Procedure
Description: Undergo home-based HPV screening

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Screening Method
Description: Undergo standard of care Pap test screening

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Screening Method
Description: Undergo home-based HPV screening
Study: NCT03254524

Intervention type: OTHER
Intervention: Statewide Planning and Research Cooperative System Database
Description: The Statewide Planning and Research Cooperative System (SPARCS) is a comprehensive data reporting system created to collect information on discharges from hospitals. SPARCS currently collects patient level detail on patient characteristics, diagnoses and treatments, services, and charges for every hospital discharge, ambulatory surgery patient, and emergency department admission in New York State.
Study: NCT03171389

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ponatinib 30 MG
Description: Ponatinib: once-daily oral dose of 30mg. A cycle of treatment is defined as 28 days. Doses may be reduced to manage drug-related adverse events and may be re-escalated once events resolve.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ponatinib 30 MG
Description: Ponatinib: once-daily oral dose of 30mg. A cycle of treatment is defined as 28 days. Doses may be reduced to manage drug-related adverse events and may be re-escalated once events resolve.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ponatinib 30 MG
Description: Ponatinib: once-daily oral dose of 30mg. A cycle of treatment is defined as 28 days. Doses may be reduced to manage drug-related adverse events and may be re-escalated once events resolve.